Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2- ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: A hybrid pharmacophore approach

European Journal of Medicinal Chemistry

Volumn 67, Issue , 2013, Pages 1-13

  Malik, Sachin ^a   Bahare, Radhe Shyam ^b   Khan, Suroor Ahmad ^a  

^a HAMDARD UNIVERSITY   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

4 Oxoquinazoline 3(4H) carbothioamide; AMPA induced seizure; Anticonvulsant activity; Benzothiazole; Neuroprotection

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; PHENYTOIN; RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ELECTRIC SHOCK; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; QUANTITATIVE ANALYSIS; RAT; SEIZURE;

4-OXOQUINAZOLINE-3(4H)-CARBOTHIOAMIDE; AMPA INDUCED SEIZURE; ANTICONVULSANT ACTIVITY; BENZOTHIAZOLE; DHANPQHXXULONF-UHFFFAOYSA-N; NEUROPROTECTION; QABFTVHENPQHIO-UHFFFAOYSA-N;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; ELECTROSHOCK; INJECTIONS, INTRAPERITONEAL; MICE; MOLECULAR STRUCTURE; QUINAZOLINES; RATS; RATS, WISTAR; SEIZURES; THIAZOLES; THIOAMIDES;

EID: 84879807393     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.026     Document Type: Article

References (51)

1. C.E. Stafstrom, Epilepsy: a review of selected clinical syndromes and advances in basic science, J. Cereb. Blood Flow Metab. 26 (2006) 983-1004. (Pubitemid 44134073)
2. M.L. Scheurer, T.A. Pedley, The evaluation and treatment of seizures, N. Engl. J. Med. 323 (1990) 1468-1474. (Pubitemid 20384956)
3. W. Loscher, New visions in the pharmacology of anticonvulsion, Eur. J. Pharmacol. 342 (1998) 1-13. (Pubitemid 28131339)
4. A. Thiry, J.M. Dogne, C.T. Supuran, B. Masereel, Carbonic anhydrase inhibitors as anticonvulsant agents, Curr. Top. Med. Chem. 7 (2007) 855-864. (Pubitemid 46825082)
5. K.J.J. Meador, Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy, Clin. Psychiatry 64 (2003) 30-34.
6. H. Stefan, T. Feuerstein, Novel anticonvulsant drugs, Pharmacol. Ther. 113 (2007) 165-183. (Pubitemid 46017070)
7. E.J. Donner, O.C. Snead III, New generation anticonvulsants for the treatment of epilepsy in children, NeuroRX 3 (2006) 170-180. (Pubitemid 44081770)
8. M. Bialer, S.I. Johannessen, H.J. Kupferberg, R.H. Levy, E. Perucca, T. Tomson, Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII), Epilepsy Res. 61 (2004) 1-48. (Pubitemid 39296697)
9. A.V.K. Srivastava, A. Kumar, Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4(3H)-ones as potential anticonvulsant agents, Eur. J. Med. Chem. 37 (2002) 873-882. (Pubitemid 35356423)
10. A.V.K. Srivastava, A. Kumar, Synthesis of some newer derivatives of substituted quinazolinonyl-2-oxo/thiobarbituric acid as potent anticonvulsant agents, Bioorg. Med. Chem. 12 (2004) 1257-1264. (Pubitemid 38251316)
11. N. Ergenc, S. Buyuktimkin, G. Capan, G. Baktir, S. Rollas, Synthesis and evaluation of some CNS depressant properties of 3-{2-[(5-aryl-1,3,4-oxadiazol- 2yl)amino] acetamido}-2-methyl-4(3H)-quinazolinones, Pharmazie 46 (1991) 290-291.
12. S.K. Kashaw, V. Kashaw, P. Mishra, N.K. Jain, Design, synthesis and potential CNS activity of some novel 1-(4-substituted-phenyl)-3-(4-oxo-2-propyl- 4H-quinazolin-3-yl)-urea, ARKIVOC xiv (2008) 17-26.
13. M.K. Prashantha, M. Madaiaha, H.D. Revanasiddappaa, B. Veereshb, Synthesis, anticonvulsant, antioxidant and binding interaction of novel N-substituted methyl quinazoline-2,4(1H,3H)-dione derivatives to bovine serum albumin: a structure-activity relationship study, Spectrochim. Acta Part A: Mol. Biomol. Spectrosc. 110 (2013) 324-332.
14. A.S. El-Azab, K.E.H. ElTahir, Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities, Bioorg. Med. Chem. 22 (2012) 1879-1885.
15. P.P. Jimonet, F. Audiau, M. Barreau, J.C. Blanchard, A. Boireau, Y. Bour, M.A. Coleno, A. Doble, G. Doerflinger, C.D. Huu, M.H. Donat, J.M. Duchesne, P. Ganil, C. Gueremy, E. Honor, B. Just, R. Kerphirique, S. Gontier, P. Hubert, P.M. Laduron, J.L. Blevec, M. Meunier, J.M.C. Miquet, Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2- benzothiazolamines and 3-substituted-2-imino-benzothiazolines, J. Med. Chem. 42 (1999) 2828-2843. (Pubitemid 29370427)
16. P.P. Jimonet, M.M. Barreau, J.C. Blanchard, A.A. Boireau, A.A. Doble, P.P. Laduron, J.J. Lavayre, C.C. Malgouris, O.O. Piot, J.J. Pratt, Synthesis, anticonvulsant and neuroprotective activities of RP 66055, a riluzole derivative, Bioorg. Med. Chem. 2 (1994) 793-798.
17. S.P. Singh, R.S. Misra, S.S. Parmar, S.J. Brumleve, Synthesis of 2-(4-arylthiosemicarbazidocarbonylthio)benzothiazoles and their monamine oxidase inhibitory and anticonvulsant properties, J. Pharm. Sci. 64 (1975) 1245-1247.
18. H. Mattes, D. Carcache, H.O. Kalkman, M. Koller, alpha-Amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside, J. Med. Chem. 53 (2010) 5367-5382.
19. J.W. Newcomer, J.H. Krystal, NMDA receptor regulation of memory and behavior in humans, Hippocampus 11 (2001) 529-542. (Pubitemid 33100374)
20. A.S. El-Azab, K.E.H. ElTahir, M.S. Attia, Synthesis and anticonvulsant evaluation of some novel 4(3H)-quinazolinones, Monatsh. Chem. 142 (2011) 837-848.
21. M.L. Gujral, K.N. Sareen, R.P.E. Kohli, Evaluation of anticonvulsant activity of 2,3 di-substituted quinazolones: a new class of anticonvulsant drugs, Ind. J. Med. Res. 45 (1957) 207-210.
22. A.P. Bhaduri, N.M. Khanna, M.L. Dhar, Potential anticonvulsants: synthesis of 2,3-substituted 4-quinazolones & quinazolo-4-thiones, Ind. J. Chem. 2 (1964) 159-161.
23. S.R. Salimath, N.M.J. Patelshah, Synthesis of 6-halogenated. 2,3-Disubstituted-4-quinazolinones III, Ind. Chem. Soc. 33 (1956) 140-146.
24. A.S. El-Azab, K.E.H. ElTahir, Synthesis and anticonvulsant evaluation of some new2, 3,8-trisubstituted-4(3H)-quinazoline derivatives, Bioorg. Med. Chem. Lett. 22 (2012) 327-333.
25. R.W.J. Olsen, GABA-benzodiazepine-barbiturate receptor interaction, J. Neurochem. 27 (1981) 1-3.
26. L. Lacoste, S. Bartolucci, J.C. Lapointe, Pentylenetetrazole inhibits glutamate dehydrogenase and aspartate aminotransferase, and stimulates GABA amino transferase in homogenates from rat cerebral cortex, Can. J. Physiol. Pharmacol. 66 (1988) 1135-1138. (Pubitemid 18259797)
27. R. Okada, H. Negishi, The role of the nigrotegmental GABAergic pathway in the propagation of pentylenetetrazole-induced seizures, Brain Res. 480 (1989) 383-387. (Pubitemid 19050241)
28. S.N. Pandeya, P. Yogeeswari, J.P. Stables, Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones, Eur. J. Med. Chem. 35 (2000) 879-886.
29. P. Yogeeswari, D. Sriram, L.R.J. Suniljit, S.S. Kumar, J.P. Stables, Anticonvulsant and neurotoxicity evaluation of some 6-chlorobenzothiazolyl-2- thiosemicarbazones, Eur. J. Med. Chem. 37 (2002) 231-236. (Pubitemid 34251186)
30. N. Siddiqui, W. Ahsan, Synthesis, anticonvulsant and toxicity screening of thiazolyl-thiadiazole derivatives, Med. Chem. Res. 20 (2011) 216-226.
31. N. Siddiqui, A. Rana, S.A. Khan, S.E. Haque, M.F. Arshad, S. Ahmed, W. Ahsan, Synthesis and preliminary screening of benzothiazol-2-yl thiadiazole derivatives for anticonvulsant activity, Acta Pharm. 59 (2009) 441-451.
32. H.W. Grimmel, A. Guentin, A new synthesis of 4-quinazolones, J. Am. Chem. Soc. 68 (1946) 542-543.
33. X. Dai, S. Virgil, Synthesis of 2-heterosubstituted quinazolinone atropisomeric phosphine ligands by direct lithiation of a 2-unsubstituted quinazolinone system, Tetrahedron: Asymmetry 10 (1999) 25-29. (Pubitemid 29089204)
34. F. Azam, I.A. Alkskas, S.L. Khora, O. Prakash, Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants, Eur. J. Med. Chem. 44 (2009) 203-211.
35. P. Yogeeswari, D. Sriram, R. Thirumurugan, J.V. Raghavendran, K. Sudhan, R.K. Pavana, J.P. Stables, Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design, J. Med. Chem. 48 (2005) 6202-6211. (Pubitemid 41428975)
36. R.J. Porter, J.J. Cereghino, G.D. Gladding, B.J. Hessie, H.J. Kupferberg, B. Scoville, B.G. White, Antiepileptic drug development program, Cleve. Clin. Q. 51 (1984) 293-305. (Pubitemid 14038030)
37. H.S. White, J.H. Woodhead, K.S. Wilcox, J.P. Stables, H.J. Kupferberg, H.H. Wolf, in: R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.), Antiepileptic Drugs, Lippincott, Philadelphia, PA, 2002, pp. 43-44.
38. J.T. Litchfield, F.A. Wilcoxon, A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 96 (1949) 99-113.
39. A. Chimirri, G.D. Sarro, A.D. Sarro, R. Gitto, S. Grasso, S. Quartarone, M. Zappala, P. Giusti, V. Libri, A. Constanti, A.G. Chapman, 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists, J. Med. Chem. 40 (1997) 1258-1269. (Pubitemid 27175105)
40. N.W. Dunham, T.A. Miya, A note on a simple apparatus for detecting neurological deficit in rats and mice, J. Am. Pharm. Assoc. Sci. 46 (1957) 208-209.
41. W.C. Brown, D.O. Schiffman, E.A. Swinyard, L.S. Goodman, Comparative assay of antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test, J. Pharmacol. Exp. Ther. 107 (1953) 273-283.
42. M.E. Barton, B.D. Klein, H.H. Wolf, H.S. White, Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy, Epilepsy Res. 47 (2001) 217-227. (Pubitemid 34008465)
43. R.F. Kaminski, M.R. Livingood, M.A. Rogawski, Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice, Epilepsia 45 (2004) 864-867. (Pubitemid 38890989)
44. R. Thirumurugan, D. Sriram, A. Saxena, J.P. Stables, P. Yogeeswari, 2,4-Dimethoxyphenyl semicarbazones with anticonvulsant activity against three animal models of seizure: synthesis and pharmacological evaluation, Bioorg. Med. Chem. 14 (2006) 3106-3112.
45. I. Nydick, F. Wrobelewski, J.S. Ladue, Evidence for increased serum glutamic oxalacetic transaminase (SGO-T) activity following graded myocardial infarcts in dogs, Circulation 22 (1955) 161-163.
46. S. Reitman, S. Frankel, A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases, Am. J. Clin. Pathol. 28 (1957) 56-58.
47. E. Roberts, Methods in Enzymology, vol. VI, Academic Press, New York, 1962, p. 612.
48. G.B. De Sarro, E. Ongini, R. Bertorelli, U. Aguglia, A. De Sarro, Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA:2 mice, Eur. J. Pharmacol. 262 (1994) 11-19. (Pubitemid 24271831)
49. S.D. Donevan, M.A. Rogawski, GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA: kainate receptor responses, Neuron 10 (1993) 51-59. (Pubitemid 23045425)
50. M.A. Rogawski, Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines, Trends Pharmacol. Sci. 14 (1993) 325-331. (Pubitemid 23282161)
51. I. Tarnawa, S. Farkas, P. Berzsenyi, A. Pataki, F. Andrasi, Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466, Eur. J. Pharmacol. 67 (1989) 193-199. (Pubitemid 19215469)